myFibroScan vs CLDF ACE 2.0

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.

The CLDF ACE 2.0 app is designed for health care professionals interested in liver disease. The content of this app is for educational purposes only and designed to provide useful information for providers and stakeholders to better understand how to effectively manage various liver conditions based on expert opinions and liver related clinical research and published articles. CLDF ACE 2 .0 is your free, customized, open educational exchange for expert opinions, conference coverage, emerging data, management algorithms, AI, and other unique forms of digital education. Chronic Liver Disease Foundation Application for Clinical Exchange (CLDF ACE 2.0) is an educational based platform that provides tailored medical education, tools, resources, and information for Health Care Providers in the field of Liver and Gastroenterology Diseases. CLDF ACE 2.0 is an educational exchange application that ensures all users opt in and must agree to its terms and conditions before using the CLDF application. This application is for education only and is not intended for medical advice or consultation.